channels where binding of a diverse range of first messengers, including many peptide hormones, growth factors, and neurotransmitters, to their receptors leads to activation of PLC and the generation of IP 3 (4, 12, 17, 18) . The subsequent binding of IP 3 to the IP 3 receptor (IP 3 R) on the endoplasmic reticulum (ER) leads to release of Ca 2ϩ from the ER Ca 2ϩ storage sites, which, in turn, activates PM Ca 2ϩ -permeable channels and Ca 2ϩ influx. This process of store-dependent Ca 2ϩ influx is often referred to as store-operated Ca 2ϩ influx (or capacitative calcium entry) and the PM Ca 2ϩ -permeable channels as "storeoperated" Ca 2ϩ channels (SOC). The molecular components of SOC signalplexes and the mechanism and regulation of SOC activity are not fully understood, although recent progress is providing new insights into the basic mechanisms. It has been shown that some members of the TRPC Ca 2ϩ -permeable channels, most notably members of the TRPC1/TRPC4/ TRPC5 grouping, function as the PM Ca 2ϩ -influx pathways in many SOC responses (1, 11, 12) . While the IP 3 R and other associated proteins are now known to be components of the TRPC SOC signalplex, it has most recently been shown that stromal interaction molecule 1 (STIM1) may be a central player in this process (10, 13) . STIM1, an ER resident protein, appears to function as an ER Ca 2ϩ sensor which, on store depletion, translocates toward the plasma membrane as an essential signaling component of the SOC complex. It appears to provide the critical link that must exist between the ER and PM in any SOC response (10, 13) . Indeed, it has now been shown that on depletion of Ca stores STIM1 associates with TRPC1, TRPC4, and TRPC5, apparently to give rise to their SOC function (19) . However, our understanding of the regulation of TRPC channel activity at the PM is still not well understood.
While the molecular complex underlying the SOC response is beginning to be unraveled, our understanding of the regulatory pathways controlling the activity of SOC channels at the PM, and hence Ca 2ϩ influx, is still poorly defined, as heretofore noted (12) . The recent article by Sansom's group (15) provides evidence of a new key player in control of TRPC4-based SOC in human renal mesangial cells. In these cells, TRPC4 (16) and probably TRPC1 (2, 14) have been shown to be components of the SOC complex. Dysfunctional control of Ca 2ϩ signaling in many cells, including mesangial cells, is thought to underlie various Ca 2ϩ -based malfunctional states that can lead to cellular dedifferentiation and proliferative pathologies (see Ref. 15) . Recent studies have shown that cGMP, through activation of cGMP-dependent protein kinase (PKG), may negatively regulate Ca 2ϩ signaling and SOC activity (6, 8) . These studies point to upstream nitric oxide (NO), cGMP, and PKG as an important second messenger pathway that may down modulate SOC activity. Hence, the NO-cGMP-PKG pathway may be a key pathway in suppressing cellular proliferation and dedifferentiation of various cell types, including mesangial cells. However, the molecular players underlying this NO-cGMP-PKG-mediated downregulation of SOC have remained elusive.
What Sansom and coworkers (15) discovered in the current study was that a separate phosphoprotein, namely, vasodilatorstimulated phosphoprotein (VASP), may be a component of the SOC machinery that is responsible for negative regulation of TRPC4 in mesangial cells. The Ena/VASP family of proteins are typically associated with regulation of actin assembly and cell motility, although other functions are beginning to emerge (7, 9) . The VASP protein is a substrate for PKG and cAMP-dependent protein kinases (PKA), but where the serine 239 site (Ser239) functions as a specific PKG phosphorylation site (7, 9) . Furthermore, VASP is highly expressed in mesangial cells and many other cells (3, 5) . Sansom's group (15) found that activation of the NO-cGMP-PKG pathway, but not the cAMP-PKA pathway, resulted in an attenuated TRPC4-SOC response, but the response was restored by specific inhibition of PKG-1␣, the dominant PKG isoform expressed in these cells. Most importantly was the demonstration that PKG activation in these cells led to phosphorylation of VASP at Ser239. Western blot, coimmunoprecipitation, and coimmunostaining experiments demonstrated that phosphorylation of VASP at Ser239 (P-Ser239-VASP) caused VASP to associate with TRPC4. VASP did not associate with TRPC4 if it were not phosphorylated at Ser239. The authors speculate that the association of P-Ser239-VASP with TRPC4 must inhibit TRPC4 activation, potentially by dissociation of P-Ser239-VASP-associated TRPC4 from a SOC complex. Regardless of the underlying mechanism, the authors have demonstrated that VASP is a key player in the NO-cGMP-PKG-induced regulation of TRPC4 and SOC in human mesangial cells. The study provides the first evidence as to the potential mechanism of PKG-induced downregulation of SOC activity and that a PKG substrate may associate with TRPC4 to modulate the SOC response. Since PKG is widely expressed in many cell types, it is likely that VASP, or other phosphoproteins with VASP homologies, may play similar roles in regulating the TRPCbased SOC responses. Finally, the findings may also have implications for pharmacological intervention of SOC-based diseases using VASP or other TRPC-associated phosphoproteins as primary drug targets. Hence, the current study has broad implications for the SOC field, providing new insights into the molecular basis of regulation of SOC-based Ca 2ϩ signaling while opening potential doors to new drug targets that may be accessible for pharmacological modulation of dysfunctional Ca 2ϩ states.
